Skip to content
PoliticalRepoPoliticalRepo

Ireland · Question · written

PQ 268

268. Deputy David Cullinane asked the Minister for Health the differences in the reimbursement and commercial engagement processes followed in respect of medications (details supplied) following the relevant NCPE recommendations; the objective factors which account for the differing level and pace of commercial engagement and the different reimbursement outcomes in each case, including considerations relating to clinical need, cost effectiveness, budget impact, alternative treatments and any other relevant factors; and if she will make a statement on the matter. [70806/26]

askedIreland· Dáil Éireann· EN

Introduced

7 October 2026

Last action

7 October 2026 · Medicinal Products

Status

written

Sponsors

David Cullinane

Subjects

Budget

Source updated

7 October 2026

Budget

Summary

268. Deputy David Cullinane asked the Minister for Health the differences in the reimbursement and commercial engagement processes followed in respect of medications (details supplied) following the relevant NCPE recommendations; the objective factors which account for the differing level and pace of commercial engagement and the different reimbursement outcomes in each case, including considerations relating to clinical need, cost effectiveness, budget impact, alternative treatments and any other relevant factors; and if she will make a statement on the matter. [70806/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 October 2026

    Medicinal Products

    268. Deputy David Cullinane asked the Minister for Health the differences in the reimbursement and commercial engagement processes followed in respect of medications (details supplied) following the relevant NCPE recommendations; the objective factors which account for the differing level and pace of commercial engagement and the different reimbursement outcomes in each case, including considerations relating to clinical need, cost effectiveness, budget impact, alternative treatments and any other relevant factors; and if she will make a statement on the matter. [70806/26]

    Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

Medicinal Products

View fileDownload file

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Medicinal Products

    xml · EN · 7 October 2026

    ViewDownloadOpen at official source

  • Question

    text · EN · 7 October 2026

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.